The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail


Janssen-Cilag International NVEU/1/14/971/009

Main Information

Active SubstancesPaliperidone palmitate (r092670)
Dosage FormProlonged-release suspension for injection
Licence HolderJanssen-Cilag International NV
Licence NumberEU/1/14/971/009

Group Information

ATC CodeN05AX Other antipsychotics
N05AX13 paliperidone


License statusAuthorised
Licence Issued26/05/2016
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back